Study Evaluating AMG 706 in Subjects With Advanced Solid Tumors

• Status: Completed
• Trial end date: 2006-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will determine the safety and pharmacokinetics of AMG 706 in subjects with advanced solid tumors.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Amgen
• Treatments: Motesanib diphosphate; Niacinamide

Criteria

Inclusion Criteria: Exclusion Criteria: